Sugi Predict

Sugi Predict / Compounds / SCHEMBL1406741

SCHEMBL1406741

SCHEMBL1406741

CC(C)(C)c1ccc(-c2cc(C(O)C#Cc3ccc(C(=O)O)cc3)cc(C(C)(C)C)c2NCc2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 2/20 0.42
▸ RARG P13631 2/20 0.42
▸ RAB9A P51151 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ EGFR P00533 1/20 0.39
▸ NR1H4 Q96RI1 6/20 0.39
▸ EPHX2 P34913 2/20 0.39
▸ RARA P10276 1/20 0.38
▸ PTGES O14684 2/20 0.36
▸ ALOX5 P09917 2/20 0.36
▸ RXRA P19793 2/20 0.35
▸ RXRB P28702 2/20 0.35
▸ RXRG P48443 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ VCP P55072 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ NR4A2 P43354 1/20 0.34
▸ NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406849 0.93 VCP (0.37) RARBRARGEGFRNR1H4EPHX2
SCHEMBL1406443 0.92 RAB9A (0.41) RARBRARGRAB9ALMNAEGFR
SCHEMBL1406342 0.88 RARB (0.44) RARBRARGNR1H4EPHX2RARA
SCHEMBL1406664 0.86 RARB (0.42) RARBRARGRAB9ANR1H4EPHX2
SCHEMBL1406969 0.85 MEN1 (0.38) RARBRARGRAB9ARARARXRA
SCHEMBL1406441 0.83 RARB (0.42) RARBRARGRAB9AEGFRNR1H4
SCHEMBL6424179 0.81 NPC1 (0.33) RARBRARGRAB9ANR1H4RARA
SCHEMBL6419796 0.81 RAB9A (0.37) RARBRARGRAB9ALMNAEGFR
SCHEMBL1406512 0.81 LMNA (0.40) RARBRARGRAB9ALMNAEGFR
SCHEMBL1406798 0.81 LMNA (0.40) RARBRARGRAB9ALMNAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 — — EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 — — US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 — — EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 — — US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885RAB9A 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.